ABIONYX Pharma SA (EPA: ABNX)
France
· Delayed Price · Currency is EUR 1.344
-0.006 (-0.45%)
Dec 2, 2024, 9:11 AM CET
ABIONYX Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 4.86 | 4.64 | 5.25 | 0.68 | - | - | Upgrade
|
| Revenue Growth (YoY) | 2.23% | -11.65% | 678.07% | - | - | - | Upgrade
|
| Cost of Revenue | 3.92 | 4.02 | 4.62 | 0.42 | - | - | Upgrade
|
| Gross Profit | 0.93 | 0.62 | 0.64 | 0.26 | - | - | Upgrade
|
| Selling, General & Admin | 2.72 | 2.61 | 3.66 | 2.34 | 1.27 | 1.78 | Upgrade
|
| Research & Development | 1.62 | 1.52 | 1.11 | 3.84 | 1.7 | 0.74 | Upgrade
|
| Other Operating Expenses | -0.1 | -0.1 | -0.02 | 0.04 | - | - | Upgrade
|
| Operating Expenses | 4.24 | 4.03 | 4.75 | 6.21 | 2.97 | 2.53 | Upgrade
|
| Operating Income | -3.31 | -3.41 | -4.11 | -5.95 | -2.97 | -2.53 | Upgrade
|
| Interest Expense | -0.03 | -0.02 | -0.06 | -0.01 | - | -0.35 | Upgrade
|
| Interest & Investment Income | 0.08 | 0.06 | 0.01 | 0 | 0.06 | 0.2 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.04 | -0.02 | 0.04 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.16 | -0.2 | -0.08 | 0.15 | - | 4.59 | Upgrade
|
| EBT Excluding Unusual Items | -3.45 | -3.61 | -4.21 | -5.82 | -2.87 | 1.89 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.09 | 0.09 | - | - | 0.09 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.9 | - | Upgrade
|
| Pretax Income | -3.36 | -3.52 | -4.21 | -5.82 | -1.89 | 1.89 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | 0.04 | Upgrade
|
| Net Income | -3.36 | -3.52 | -4.21 | -5.82 | -1.89 | 1.85 | Upgrade
|
| Net Income to Common | -3.36 | -3.52 | -4.21 | -5.82 | -1.89 | 1.85 | Upgrade
|
| Shares Outstanding (Basic) | 31 | 29 | 28 | 25 | 23 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 29 | 28 | 25 | 23 | 21 | Upgrade
|
| Shares Change (YoY) | 11.19% | 4.94% | 12.41% | 5.92% | 11.21% | 13.65% | Upgrade
|
| EPS (Basic) | -0.11 | -0.12 | -0.15 | -0.23 | -0.08 | 0.09 | Upgrade
|
| EPS (Diluted) | -0.11 | -0.12 | -0.15 | -0.23 | -0.08 | 0.09 | Upgrade
|
| Free Cash Flow | -3.09 | -3.8 | -3.52 | -6.86 | -0.7 | -3.95 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.13 | -0.13 | -0.28 | -0.03 | -0.19 | Upgrade
|
| Gross Margin | 19.19% | 13.32% | 12.11% | 38.37% | - | - | Upgrade
|
| Operating Margin | -68.12% | -73.53% | -78.24% | -881.78% | - | - | Upgrade
|
| Profit Margin | -69.15% | -75.82% | -80.08% | -862.52% | - | - | Upgrade
|
| Free Cash Flow Margin | -63.67% | -81.94% | -67.10% | -1016.00% | - | - | Upgrade
|
| EBITDA | -3.19 | -3.29 | -3.99 | -5.83 | -2.95 | -2.51 | Upgrade
|
| EBITDA Margin | -65.65% | -70.91% | -75.91% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.12 | 0.12 | 0.12 | 0.12 | 0.02 | 0.01 | Upgrade
|
| EBIT | -3.31 | -3.41 | -4.11 | -5.95 | -2.97 | -2.53 | Upgrade
|
| EBIT Margin | -68.12% | -73.53% | -78.24% | - | - | - | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 2.01% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.